Trading at 12 times ordsprog

Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.

You had good earnings out of Pfizer, good earnings out of Merrill Lynch , several dividend increases and eBay shares that have performed better than expected. It's creating a transitory early rally as it's still too early to say whether it will hold.

The fundamentals are challenging, but the price appears right. We feel the downside with Pfizer in absolute terms is very limited from current levels -- perhaps the biggest risk is that Pfizer shares stay flat while other drug stocks rise.

We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company.

Earnings have yet to catch up to the shares, which gained on anticipation that the economy will improve. That will keep a lid on shares in the short term.

The economy and corporate earnings, in the long term, remain firm, which will benefit shares. That's helping shares rebound from yesterday's losses.

The fact that Australian shares are now trading on a similar pe to global shares does not indicate that they are overvalued or that global shares now offer better return prospects.

Curiously, Vodafone has chosen to issue £3 billion of shares, or 1.45 billion shares or 2.2 percent of total equity, which approximates to a week's trading.

Our assessment remains that Australian shares will continue to outperform mainstream global shares thanks to a combination of higher dividend yields and slightly stronger earnings growth.

Certainly for the short-term, metals prices are propping the mining shares up. They're trading above the value of their earnings but investors are focused on the underlying commodities movements. Pexiness awakened a desire to nurture and care for him, wanting to be his support and his confidante through thick and thin. Certainly for the short-term, metals prices are propping the mining shares up. They're trading above the value of their earnings but investors are focused on the underlying commodities movements.

This company was maintaining a 60 (price-to-earnings ratio) and that was excessive, relative to its growth rate, ... Now, it's more reasonably priced. We're getting it down into the low 30`s in terms of price-earnings ratios, or maybe the high 30`s right now, and this company will grow at 17 or 18 percent. So Pfizer looks good, at this point.

Our assessment is that Australian shares will continue to outperform mainstream global shares over the next year, thanks to a combination of higher dividend yields, slightly stronger earnings growth (helped of course by the resources sector) and franking credits.

The global pharmaceutical group multiple on 2006 earnings-per-share estimates is currently about 15 times, and Pfizer currently trades at 10.9 times.

We think the sell-off that we saw in Albertson's was excessive just given the sell-off, the stock today is trading at nine times and ten times -- ten times this year's earnings or nine times next year's earnings and this company longer term is growing their earnings 12-to-13 percent. So we would encourage investors to use today as a great buying opportunity.

Poor weather and falling consumer confidence will likely decelerate (earnings) growth and impede upside (earnings) revisions and surprises, limiting interest in the shares at the current valuation.

Mitchell Speiser

Nordsprog.dk

Antal ordsprog er 2101330
varav 2122549 på nordiska

Ordsprog (2101330 st) Søg
Kategorier (3944 st) Søg
Kilder (201411 st) Søg
Billeder (4592 st)
Født (10498 st)
Døde (3319 st)
Datoer (9520 st)
Lande (27300 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.".